Bharat Biotech Gets Indian Approval for COVID-19 Vaccine Trials
Indian drugmaker Bharat Biotech has received approval to begin clinical trials of its COVID-19 vaccine candidate. It is the first trial approval for a domestic vaccine candidate.
The Hyderabad-based company is developing Covaxin, an inactivated vaccine derived from a strain of the SARS-CoV-2 virus isolated at India’s National Institute of Virology.
The phase 1/2 trials are scheduled to get underway across India in July.